Table I.
Summary of cidofovir in reviewed clinical trials.
| Study | Year | Number of patients | Median age (years) | Pre-treat mean Derkay score | Pre-treat surgical rate (surgery per year) | Post-treat mean Derkay score | Post-treat surgical rate (surgery per year) | HPV type | Mean concentration (mg/ml) | Results and conclusions |
|---|---|---|---|---|---|---|---|---|---|---|
| Ablanedo-Terrazas et al. 28 | 2022 | 4, 1 Jo | 17 | 23.5 | 3.4 | 0.5 | 0 | 5 | Decrease in the Derkay severity score with IL cidofovir | |
| 3 Ao | ||||||||||
| Jackowska et al. 29 | 2019 | 42 | 30 | 8 (mean of procedures before cidofovir) | 2.5 (mean of procedures after cidofovir) | Treatment with intraepithelial cidofovir injections and CO2 laser debulking can lead to a nearly normal voice. 22 complete remissions. 20 partial remissions | ||||
| 3 Jo | ||||||||||
| 39 Ao | ||||||||||
| McMurray et al. 30 | 2008 | 19 | 32 | 13.2 | 2.7 | 0.3-5 | Cidofovir demonstrate a reduction in severity index score | |||
| 3 Jo | ||||||||||
| 16 Ao | ||||||||||
| Naiman et al. 31 | 2006 | 17 | 4 | 7.67 (CR) | 0 (CR) | 5-7.5 | 12 complete remissions. 5 partial remissions | |||
| 17 Jo | 9.75 (PR) | 4.25 (PR) | ||||||||
| Chung et al. 32 | 2006 | 11 | 7 | 13.7 | 7.4 | 2.6 | 6.9 | 5 | The effectiveness of cidofovir as an adjuvant treatment for RRP remains unproven, but the possibility of some therapeutic effect is modestly suggested. 5 complete remissions. 6 partial remissions | |
| 11 Jo | ||||||||||
| Peyton Shirley et al. 33 | 2004 | 11 | 2 | 11.9 | HPV 11 | 5-7.5 | Cidofovir is a useful tool adjunctive therapy in RRP. Significant response 27%, partial response 18%, no response 55% | |||
| 11 Jo | HPV 6 | |||||||||
| Chhetri et al. 34 | 2003 | 5 | 9.2 | 1 | HPV 11 | 5 | A scheduled protocol for the treatment of Jo-RRP with cidofovir, with increasing interval between treatments, is effective in controlling this disease | |||
| 5 Jo | HPV 6 | |||||||||
| Bielamowicz et al. 35 | 2002 | 13 | 48 | 10 | 2.15 | 0 | 0 | HPV 11 | 4.17-6.25 | Intralesional injection of cidofovir is an excellent treatment option with limited local and systemic toxicities. The long-term remission rates for patients with respiratory papilloma are unknown |
| 13 Ao | HPV 6 | |||||||||
| Pransky et al. 36 | 2000 | 10 | 7 | 19.6 | 19 (mean of procedures before cidofovir) | 12.7 | 2.2 (mean of procedures after cidofovir) | HPV 11 | Cidofovir therapy is an effective and beneficial treatment | |
| 10 Jo | HPV 6 |
Jo: Juvenile onset; Ao: Adult onset; CR: Complete Response; PR: Partial Response.